BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15217926)

  • 1. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
    Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y
    Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
    Pierri I; Clavio M; Beltrami G; Cavaliere M; Lanza L; Miglino M; Canepa L; Pietrasanta D; Ballerini F; Quintino S; Gatto S; Celesti L; Carrara P; Varese P; Gobbi M
    J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
    Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
    Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Pivnik AV; Khoroshko ND; Ol'shanskaia IuV; Tikhonova LIu; Maslova ER; Kulikov SM
    Ter Arkh; 1999; 71(7):13-20. PubMed ID: 10481861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
    Lemez P; Gáliková J; Haas T
    Neoplasma; 2000; 47(1):41-7. PubMed ID: 10870686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol).
    Montastruc M; Reiffers J; Stoppa AM; Sotto JJ; Corront B; Marit G; Maraninchi D; Michallet M; Gastaut JA; Broustet A
    Nouv Rev Fr Hematol (1978); 1990; 32(2):147-52. PubMed ID: 2198531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
    Godwin J
    J Natl Cancer Inst Monogr; 1995; (19):31-5. PubMed ID: 7577202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
    Qiau Z; Wang C; Yang L
    Zhonghua Nei Ke Za Zhi; 1996 Aug; 35(8):545-8. PubMed ID: 9594148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide in the management of leukemia: a review.
    Bishop JF
    Semin Oncol; 1991 Feb; 18(1 Suppl 2):62-9. PubMed ID: 1992536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of elderly patients with AML: results of an individualized approach.
    Hernández-Boluda JC; Sierra J; Esteve J; Nomdedeu B; Montserrat E
    Haematologica; 1998 Jan; 83(1):34-9. PubMed ID: 9542321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preliminary study on postremission therapy courses in acute myeloid leukemia].
    Mi Y; Bian S; Xue Y
    Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):520-3. PubMed ID: 11769676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low dose cytarabine in the treatment of acute myeloid leukemia. Apropos of 41 cases].
    Frikha M; Elloumi M; Bouaziz M; Daoud J; Mseddi S; Khanfir A; Gargouri J; Souissi T
    Bull Cancer; 1996 Dec; 83(12):996-1001. PubMed ID: 9116380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.